TB-500 is used here for the synthetic, N-terminally acetylated seven-amino-acid peptide Ac-LKKTETQ, corresponding to residues 17–23 of thymosin β4 (Tβ4). It is a fragment, not the full-length Tβ4 protein. - TB-500: Ac-LKKTETQ, an acetylated heptapeptide fragment. - Full-length thymosin β4 (Tβ4): a 43-amino-acid protein that contains the LKKTETQ sequence within its actin-binding region. The shared sequence does not make the two molecules interchangeable. Their molecular sizes differ substantially, and findings about full-length Tβ4 should not be presented as direct TB-500 results unless the fragment itself was tested. Esposito and colleagues synthesized and characterized the N-acetylated Tβ4 residues 17–23 fragment identified in TB-500. Ho and colleagues developed an LC–MS method and detected TB-500 and its metabolites in plasma and urine from horses after administration. That analytical study supports identification and detection in an equine setting; it is not a human pharmacokinetic or clinical-efficacy study. An earlier mouse wound-repair study tested a synthetic seven-residue peptide containing the LKKTETQ actin-binding domain and reported activity in that model. The paper describes the tested peptide as LKKTETQ; its results should not be conflated with proof of human benefit or with every result reported for intact Tβ4. Full-length Tβ4 studies describe the biology of the 43-amino-acid protein, including its interactions with actin. Such work helps explain why the region containing LKKTETQ is studied, but does not by itself establish that the isolated acetylated fragment has all the same effects, distribution, potency, or duration. Other short Tβ4-derived sequences are also distinct. For example, Ac-SDKP (residues 1–4) is not TB-500 (Ac-LKKTETQ, residues 17–23); findings about one fragment must not be assigned to the other. The cited work does not establish human safety, efficacy, dosing, or pharmacokinetics for TB-500. Animal, cell, intact-protein, and different-fragment findings are identified by what was actually tested and should not be generalized across molecules. These references also do not verify the identity, composition, or performance of any commercial product or blend. 1. Philp D, et al. Thymosin β4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003;11(1):19–24. doi:10.1046/j.1524-475X.2003.11105.x(https://doi.org/10.1046/j.1524-475X.2003.11105.x). The paper tested the seven-residue LKKTETQ sequence in mouse wound-repair models. 2. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733–738. PMID 22962027(https://pubmed.ncbi.nlm.nih.gov/22962027/). Fragment synthesis and analytical characterization. 3. Ho ENM, et al. Doping control analysis of TB-500, a sy
TB-500: Acetylated Thymosin β4 Fragment Research Guide
TB-500 refers to the synthetic N-terminally acetylated seven-amino-acid thymosin β4 fragment Ac-LKKTETQ (residues 17–23). It is distinct from the full-length, 43-amino-acid thymosin β4 protein; evidence about one is not automatically evidence about the other.